CD274 and cancer: In addition, combination therapy using anti-PD-1 and PD-L1 antibodies with other drugs is necessary to improve the response rate of cancer treatment, and substances that inhibit PD-1 signaling or inhibit PD-1 or PD-L1 expression may be potential candidates.